The earnings call highlighted significant progress in clinical trials, a strong pipeline with promising collaborations, and a robust financial position. Despite a shift in focus for the IRAK4 program, the overall trajectory remains positive.
Company Guidance -
Q3 2025
During the Kymera Therapeutics Second Quarter 2025 Results Call, the company provided guidance on its strategic developments and financial outlook. The call highlighted significant progress in their STAT6 program, with positive results from the KT-621 trial in healthy volunteers surpassing target product profiles, suggesting potential as a first-in-class treatment for dermatological and respiratory diseases. The company also announced two partnerships, one with Gilead for a CDK2 degrader program with potential payments up to $750 million, and another with Sanofi, which opted into the IRAK4 program, potentially bringing $975 million in milestones. Financially, Kymera raised $288 million in a follow-on offering, increasing its cash position to $1 billion, extending its runway into the second half of 2028. The company plans to initiate several Phase III studies and further develop its early-stage pipeline.
Positive Results for KT-621
Completed the first KT-621 trial in healthy volunteers with results exceeding expectations, surpassing target product profile, and demonstrating potential as a first-in-class treatment for dermatological and respiratory diseases.
Strong Pipeline and Collaborations
Selected a follow-on STAT6 degrader with strong potency and advanced it through all required IND-enabling studies. Announced partnerships with Gilead for the CDK2 program and Sanofi for the IRAK4 program, potentially realizing significant milestones.
Extended Cash Runway
Extended cash runway into the second half of 2028 with a cash position of $1 billion, providing resources to advance multiple programs into Phase III studies.
Kymera Therapeutics (KYMR) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KYMR Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 11, 2025
$40.62
$37.68
-7.24%
May 09, 2025
$30.77
$30.07
-2.27%
Feb 27, 2025
$35.36
$30.25
-14.45%
Oct 31, 2024
$47.67
$46.17
-3.15%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kymera Therapeutics (KYMR) report earnings?
Kymera Therapeutics (KYMR) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).
What is Kymera Therapeutics (KYMR) earnings time?
Kymera Therapeutics (KYMR) earnings time is at Oct 30, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.